Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,932.00
Bid: 1,942.00
Ask: 1,944.00
Change: -41.00 (-2.08%)
Spread: 2.00 (0.103%)
Open: 1,967.00
High: 1,973.00
Low: 1,926.00
Prev. Close: 1,973.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Johnston Press, Direct Line, Hikma Pharmaceuticals

Thu, 04th Aug 2016 11:01

(ShareCast News) - Johnston Press shares plunged on Thursday as Numis placed its rating and target price 'under review' after the company swung to a first half loss.For the 26 weeks to 2 July, the company posted a statutory pre-tax loss of £183.7m versus a £2.2m profit the year before, as it booked a £183.6m non-cash impairment reflecting a change of assumptions on its publishing titles and print assets.Advertising revenues were down 17.9% in the first quarter but improved marginally, with a 15% drop in the second quarter despite the impact of the run-up to and uncertainty following the UK's vote to leave the European Union in June.Chief executive Ashley Highfield said the market continues to be challenging and uncertainty surrounding the outcome of the Brexit negotiations has caused further softness in some segments of the advertising market, in June and July.Numis said the half year results came in below its estimates at every level."Our key issue at Johnston remains debt which has risen to £209m (from £179.4m) representing almost 4x our annualised EBITDA."This material debt pile, relative to cashflows, in combination with the declining and uncertain trading environment place a significant question mark on the equity value in the business."Numis said it expects to cut estimates "reasonably sharply" in both fiscal years 2016 and 2017. Direct Line Insurance Group's rating has been downgraded to 'hold' from 'buy' by Berenberg as the broker said "questions remain about earnings sustainability"."We believe there is some risk regarding the sustainability of Direct Line's earnings," Berenberg said in a note on Wednesday."High reserve releases, lower than forecast cost savings and a shrinking direct market all cast doubt on future earnings."Berenberg said older accident years have been incredibly profitable for Direct Line but these years are now contributing increasingly less releases.The broker said it does not expect to see the same developments in more recent accident years. Berenberg believes it will be difficult for management to offset falling reserve releases with the current accident year and operating improvements."As reserve releases decline, we expect earnings to be flat at best, thus we believe it will be challenging to grow the dividend from here," the broker said.Berenberg reiterated a target price of 406p.Direct Line on Tuesday posted its half year report for the six months to 30 June on Tuesday. Operating profit fell 5% to £316.9m, hurt by lower investment gains and the new Flood Re levy, but the group beat its own consensus estimates of £263m. Analysts at Citi downgraded their recommendation on shares of Hikma Pharmaceuticals in the wake of the company´s trading update which was issued after the close of trading in London on 3 August.Hikma flagged new drug approvals were arriving more slowly than expected and the phasing of litigation costs at US generics.On the basis of the above, the broker´s analysts lowered their recommendation on the shares from 'buy' to 'neutral' and set a target price of 2,600p.They also lowered estimates for the drugmaker´s core 2016 earnings before interest and taxes and earnings per share by 9.0% to $367m and $1.08, respectively - below the equivalent figures of $420m and $1.22 expected by the consensus.EPS estimates from 2017 onwards were cut by between 2% and 5% from 2017 onwards, with rates in foreign exchange markets expected to be an "incremental headwind".What was Citi´s view? "Developments at US Generics at best can be described as a 'short term hiccup'. At worse, sentiment concerns around the revenue/margin potential from the Roxane pipeline will increase, which is not helped by the lack of clarity on the pipeline given commercial sensitivities until 2017."If one were to cut his Roxane pipeline estimates by half, that would lead to EPS downgrades of between -15.0% and -20.0%, Citi said.Citi estimated the company´s net present value (NPV) at 2,900p, with a weighted average cost of capital of 8.0%, a terminal growth value (the rate at which free cash flows are expected to grow for eternity) of 2.0% and cable´s exchange rate at 1.32.
More News
6 Aug 2021 12:07

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls

Read more
6 Aug 2021 09:03

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near

Read more
6 Aug 2021 08:40

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

TOP NEWS: Hikma hikes Generics guidance as interim profit swells

Read more
6 Aug 2021 07:42

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance

Read more
6 Aug 2021 07:22

Hikma lifts FY generics guidance as first-half profits, revenue jump

(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.

Read more
30 Jul 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
14 Jul 2021 19:38

IN BRIEF: Arecor ends first half of 2021 with solid cash position

IN BRIEF: Arecor ends first half of 2021 with solid cash position

Read more
13 Jul 2021 10:00

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight

Read more
1 Jul 2021 09:51

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart

Read more
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more
30 Apr 2021 17:01

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

Read more
30 Apr 2021 08:58

TOP NEWS: Hikma Pharma confident after promising start to year

TOP NEWS: Hikma Pharma confident after promising start to year

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.